Extrait

To assess the safety and efficacy of unrelated donor umbilical cord blood transplantation (UCBT) in a multi-institution UK setting where the use a myeloablative preparative regimen is indicated. The anti-malignancy effect of this treatment is achieved by a combination of intensive chemoradiotherapy and the 'graft vs. malignancy' (GVM) effect. The advantage of this approach is the increased likelihood of destroying the malignant cells and a reduced risk of graft rejection as the bone marrow is better prepared to accept the transplant than with reduced intensity conditioning. However, the treatment may be less well tolerated by some patients and therefore patients of advanced age or with impaired organ function are not eligible for this trial.

Critère d'inclusion

• Haematological Disorders

Liens

• euctr
• ictrp